, , Dermatomyositis, Featured, News
MSU and TMA are leading the first-ever Adult Dermatomyositis Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on June 7, 2024....
Join our House, Myositis Support on Clubhouse, for myositis patients and caregivers, for support, education, special guests, collaborations, and...
Priovant Therapeutics joins MSU to discuss The Valor Study for Dermatomyositis, a phase 3 clinical trial for Adult Dermatomyositis....
, , Dermatomyositis, Featured, Myositis Treatments
The study provided efficacy data for Octagam 10%, which was approved for dermatomyositis by the US Food and Drug...
If you are living with dermatomyositis, polymyositis, or antisynthetase syndrome, join the third Wednesday of each month for...
, , Dermatomyositis, Featured, Video
We hosted Priovant Therapeutics to discuss The Valor Study, a phase 3 clinical trial for adult dermatomyositis. Learn all...
Please join us for a webinar about the new VALOR study. The purpose of the VALOR Study is to...
Dermatomyositis and Sun Protection, Dr. Graham makes it clear the sun can cause flares. She talks about sunscreens and...
Dr. Graham educates about the skin manifestations of myositis, sharing the various DM rashes, cosmetic cover-ups, information and tips...
Co-authors of “Pain profile and opioid medication use in patients with idiopathic inflammatory myopathies”, published in Rheumatology discuss the...
, , Dermatomyositis, Featured, News, Video
Watch the recording of our fireside chat, The Power of Our Voice: FDA Listening Session for Adult Dermatomyositis, where...
View the summary of our first-ever FDA Listening Session on Adult Dermatomyositis. This was an opportunity to facilitate the...
Watch the recording with Alexion Pharmaceuticals to learn about the Flex Study to evaluate the safety and efficacy of...
Join MSU with Sanjay Rakhade MD, PhD, Executive Medical Director at Alexion Astra Zeneca Rare Disease Unit to learn...
, , Featured, Myositis Treatments, Research
Watch to learn about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The...
,
Learn about Octapharma’s IVIg therapy and the results of the landmark Progress in Dermatomyositis (ProDERM) study. The successful ProDERM...
, , Featured, Research
Dermatomyositis (DM) and polymyositis (PM) are rare autoimmune inflammatory myopathies characterized by muscle weakness and multiple extra-muscular manifestations that...
,
Register and join us on Rare Disease Day, Feb. 28th, for a presentation by Dr. Rohit Aggarwal reviewing current...
MSU is hosting the first FDA Listening Session on Adult Dermatomyositis on April 26, 2022. We hope the FDA will come...
AllStripes was honored to host this webinar with the Myositis Support and Understanding Association to discuss our current and...
Earn donations to Myositis Support and Understanding Association at no added cost to you by using goodshop.
© 2024 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.
